Back to Treatments

Treatment

Durvalumab

1
Conditions
300
Trials
25K
Participants
35%
Average Safety

Condition Evidence

Tracheal, bronchus, and lung cancer

300 trials · 25K participants

80% effectiveness · 35% safety
Durvalumab | DFDA